IART | |
Company type | Public |
Industry | Medical technology |
Founded | 1989[1] |
Headquarters | Princeton, New Jersey, U.S. |
Key people | Jan De Witte ( CEO) [2] |
Products |
|
Revenue | US$1.3 billion (2020) [1] |
Number of employees | approx. 3,946 (Dec. 2023) |
Website |
integralife |
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. [3] [4] Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. [3] Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds. [5] [6]
Integra LifeSciences was founded by Richard Caruso in 1989 after Caruso licensed Integra artificial skin technology from Harvard–MIT and acquired Colla-tec, a subsidiary of Marion Laboratories. [3] [7] The company became publicly traded under the NASDAQ ticker name IART. [7]
In 1996, Integra artificial skin was approved by the U.S. Food and Drug Administration. [8] The artificial skin, manufactured and patented as Integra, is now used on patients with extensive burns. [5] In 1999, the FDA approved Integra LifeSciences’ DuraGen, an absorbable implant used in neurosurgical and spinal procedures. [9]
In 2001, NMT, a company acquired by Integra in 2002, [10] received FDA approval for Licox, a brain tissue oxygen and temperature monitor. [11] [12] Licox is used to treat patients in critical care, including those suffering from traumatic brain injuries. [11]
In 2002, the FDA approved the use of Integra Dermal Regeneration Template for reconstructive surgery of burn scars. [13] In 2016, IDRT received premarket approval from the FDA for the treatment of diabetic foot ulcers. [14]
In 2018, Integra LifeSciences was included in Fortune’s list of Fastest Growing Companies. [15]
In 2023, Integra ranked #59 on Medical Design and Outsourcing’s list of largest medical technology companies in the world. [16]
In 1969, John F. Burke, a surgeon and Harvard Medical School professor, and Ioannis V. Yannas, a mechanical engineering professor of fibers and polymers at MIT, began working on a new form of artificial skin. [5] They created the first commercially reproducible artificial skin, later patented and manufactured as Integra. [5]
Integra is used to treat patients with severe burns. [5] [6] [8] The top layer, made of thin silicone, protects the patient from infection and dehydration, common causes of death after being severely burned. [5] [8] The bottom layer, made of animal tissue, acts as scaffolding where new skin will grow. [5] [17] Compared to traditional skin grafts, the use of Integra reduces pain and scarring. [5] [8] [17] [6]
Integra is also used in plastic surgery, reconstructive surgery, and to treat some forms of cancer and other skin wounds. [6] [18] [19] [20]
In October 2014, Integra LifeSciences acquired instrumentation lines from Medtronic for $60 million. [21] In January 2014, the company bought Covidien’s Confluent Surgical line of sealants and shields. [22]
In July 2015, Integra LifeSciences acquired TEI Biosciences and TEI Medical and began manufacturing their SurgiMend and PriMatrix product lines. [23] [24] Primatrix, a dermal repair scaffolding product, is used to treat diabetic foot ulcers, burns, and in other procedures. [25] [26]
In January 2017, Integra Lifesciences acquired Derma Sciences for $204 million. [27] Their TCC-EZ Total Contact Cast, used to treat diabetic foot ulcers, reduces pressure and shortens application time compared to a conventional total contact cast. [27] [28] [29]
In October 2017, Integra LifeSciences acquired Johnson & Johnson’s Codman Neurosurgery business for $1.045 billion. [30] The Codman Hakim valve was developed as a new way to treat hydrocephalus. [31] [32]
In January 2021, the company acquired regenerative medicine firm, ACell, for $400M. [33] [34]
IART | |
Company type | Public |
Industry | Medical technology |
Founded | 1989[1] |
Headquarters | Princeton, New Jersey, U.S. |
Key people | Jan De Witte ( CEO) [2] |
Products |
|
Revenue | US$1.3 billion (2020) [1] |
Number of employees | approx. 3,946 (Dec. 2023) |
Website |
integralife |
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. [3] [4] Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. [3] Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds. [5] [6]
Integra LifeSciences was founded by Richard Caruso in 1989 after Caruso licensed Integra artificial skin technology from Harvard–MIT and acquired Colla-tec, a subsidiary of Marion Laboratories. [3] [7] The company became publicly traded under the NASDAQ ticker name IART. [7]
In 1996, Integra artificial skin was approved by the U.S. Food and Drug Administration. [8] The artificial skin, manufactured and patented as Integra, is now used on patients with extensive burns. [5] In 1999, the FDA approved Integra LifeSciences’ DuraGen, an absorbable implant used in neurosurgical and spinal procedures. [9]
In 2001, NMT, a company acquired by Integra in 2002, [10] received FDA approval for Licox, a brain tissue oxygen and temperature monitor. [11] [12] Licox is used to treat patients in critical care, including those suffering from traumatic brain injuries. [11]
In 2002, the FDA approved the use of Integra Dermal Regeneration Template for reconstructive surgery of burn scars. [13] In 2016, IDRT received premarket approval from the FDA for the treatment of diabetic foot ulcers. [14]
In 2018, Integra LifeSciences was included in Fortune’s list of Fastest Growing Companies. [15]
In 2023, Integra ranked #59 on Medical Design and Outsourcing’s list of largest medical technology companies in the world. [16]
In 1969, John F. Burke, a surgeon and Harvard Medical School professor, and Ioannis V. Yannas, a mechanical engineering professor of fibers and polymers at MIT, began working on a new form of artificial skin. [5] They created the first commercially reproducible artificial skin, later patented and manufactured as Integra. [5]
Integra is used to treat patients with severe burns. [5] [6] [8] The top layer, made of thin silicone, protects the patient from infection and dehydration, common causes of death after being severely burned. [5] [8] The bottom layer, made of animal tissue, acts as scaffolding where new skin will grow. [5] [17] Compared to traditional skin grafts, the use of Integra reduces pain and scarring. [5] [8] [17] [6]
Integra is also used in plastic surgery, reconstructive surgery, and to treat some forms of cancer and other skin wounds. [6] [18] [19] [20]
In October 2014, Integra LifeSciences acquired instrumentation lines from Medtronic for $60 million. [21] In January 2014, the company bought Covidien’s Confluent Surgical line of sealants and shields. [22]
In July 2015, Integra LifeSciences acquired TEI Biosciences and TEI Medical and began manufacturing their SurgiMend and PriMatrix product lines. [23] [24] Primatrix, a dermal repair scaffolding product, is used to treat diabetic foot ulcers, burns, and in other procedures. [25] [26]
In January 2017, Integra Lifesciences acquired Derma Sciences for $204 million. [27] Their TCC-EZ Total Contact Cast, used to treat diabetic foot ulcers, reduces pressure and shortens application time compared to a conventional total contact cast. [27] [28] [29]
In October 2017, Integra LifeSciences acquired Johnson & Johnson’s Codman Neurosurgery business for $1.045 billion. [30] The Codman Hakim valve was developed as a new way to treat hydrocephalus. [31] [32]
In January 2021, the company acquired regenerative medicine firm, ACell, for $400M. [33] [34]